

# Cheryl L-L Chiang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2607159/publications.pdf>

Version: 2024-02-01

28  
papers

1,910  
citations

471371

17  
h-index

677027

22  
g-index

29  
all docs

29  
docs citations

29  
times ranked

2646  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor lysates cancer vaccine. , 2022, , 21-49.		0
2	The current clinical landscape of personalized cancer vaccines. Cancer Treatment Reviews, 2022, 106, 102383.	3.4	25
3	Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. Npj Vaccines, 2021, 6, 36.	2.9	27
4	Rate of Freeze Impacts the Survival and Immune Responses Post Cryoablation of Melanoma. Frontiers in Immunology, 2021, 12, 695150.	2.2	8
5	Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human. Cancers, 2021, 13, 4553.	1.7	6
6	Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes. , 2020, 8, e000875.		16
7	Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?. Current Opinion in Biotechnology, 2020, 65, 190-196.	3.3	9
8	Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors. Frontiers in Immunology, 2019, 10, 2283.	2.2	56
9	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Science Translational Medicine, 2018, 10, .	5.8	326
10	Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?. Vaccines, 2018, 6, 79.	2.1	7
11	In vivo cancer vaccination: Which dendritic cells to target and how?. Cancer Treatment Reviews, 2018, 71, 88-101.	3.4	32
12	Whole Tumor Antigen Vaccines: Where Are We?. Vaccines, 2015, 3, 344-372.	2.1	203
13	Potential approaches for more successful dendritic cell-based immunotherapy. Expert Opinion on Biological Therapy, 2015, 15, 569-582.	1.4	30
14	A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. Journal of Translational Medicine, 2013, 11, 149.	1.8	57
15	A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clinical Cancer Research, 2013, 19, 4801-4815.	3.2	178
16	A phase-I trial of a novel autologous oxidized whole-tumor antigen vaccine therapy for recurrent ovarian cancer. Gynecologic Oncology, 2013, 130, e11-e12.	0.6	0
17	Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology, 2013, 2, e22664.	2.1	154
18	Abstract LB-335: Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer.. , 2013, , .		2

#	ARTICLE	IF	CITATIONS
19	Abstract PR15: Autologous whole-tumor antigen combinatorial immunotherapy for recurrent ovarian cancer.. , 2013, , .		0
20	Abstract IA27: Combinatorial immunotherapy using whole tumor antigen: Evidence from phase I trials. , 2013, , .		0
21	Abstract LB-133: Vaccination with dendritic cells pulsed with autologous oxidized whole tumor lysate induced strong and long-lasting anti-tumor immunity in recurrent ovarian cancer patients. , 2012, , .		0
22	Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines. International Reviews of Immunology, 2011, 30, 150-182.	1.5	91
23	Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses. PLoS ONE, 2011, 6, e28732.	1.1	43
24	Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. Journal of Translational Medicine, 2011, 9, 198.	1.8	43
25	Hypochlorous Acid: A Natural Adjuvant That Facilitates Antigen Processing, Cross-Priming, and the Induction of Adaptive Immunity. Journal of Immunology, 2010, 184, 824-835.	0.4	281
26	Whole tumor antigen vaccines. Seminars in Immunology, 2010, 22, 132-143.	2.7	201
27	Oxidation of Ovarian Epithelial Cancer Cells by Hypochlorous Acid Enhances Immunogenicity and Stimulates T Cells that Recognize Autologous Primary Tumor. Clinical Cancer Research, 2008, 14, 4898-4907.	3.2	56
28	Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells. Cancer Immunology, Immunotherapy, 2006, 55, 1384-1395.	2.0	58